サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1576973

睡眠補助の世界市場の評価：製品別、睡眠障害別、地域別、機会、予測（2017年～2031年）

Sleep Aids Market Assessment, By Product, By Sleep Disorder, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 246 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
睡眠補助の世界市場の評価：製品別、睡眠障害別、地域別、機会、予測（2017年～2031年）
出版日: 2024年10月25日
発行: Market Xcel - Markets and Data
ページ情報: 英文 246 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の睡眠補助の市場規模は、2023年の818億米ドルから2031年に1,349億7,000万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで6.46％の成長が見込まれます。市場は、睡眠障害患者の増加、睡眠障害に関する研究開発活動の増加、熟睡とその健康上の影響に関する意識の高まりなどの影響を受け、より速いペースで成長すると予測されます。

個人の睡眠を改善し、不眠症、睡眠時無呼吸症候群、レストレスレッグス症候群などの睡眠障害を緩和する製品は、睡眠補助と呼ばれます。この選択肢には、処方薬、市販のサプリメント、ハーブ療法、そして睡眠追跡機器やスマートマットレスなどの新しい技術が含まれます。近年、睡眠補助の需要は非常に高まっています。健康やウェルビーイングの不可欠な要素として、睡眠の必要性が高まっていることが、その背景にあります。ストレスの増加、多忙なライフスタイル、技術機器の普及なども、睡眠を妨げる一因となっています。睡眠不足が健康に及ぼす悪影響がますます明らかになるにつれ、この問題を解消するために自然療法を求める人がますます増えています。パンデミックがこうしたニーズの高まりに拍車をかけ、多くの人々が不安レベルの高まりや睡眠障害を経験しています。このような状況により、顧客は治療を求めるようになり、同時に医療従事者に対する睡眠補助を勧める圧力が高まっています。精神障害について名乗り出る人が増え、製品の技術革新が進み、メンタルヘルス問題に対する寛容さが増すにつれ、睡眠補助市場は勢いを増し続け、消費者集団と企業の双方に大きな関心をもたらしています。

2023年5月、生活改善に向けた医薬品の変革に注力するバイオ医薬品企業、Avadel Pharmaceuticals plcは、米国食品医薬品局（FDA）がLUMRYZを最終承認したと発表しました。LUMRYZは、成人のナルコレプシー患者におけるカタプレキシーまたは日中の過度の眠気（EDS）の治療に、就寝時に1回服用することを目的としたオキシベートナトリウムの徐放性製剤です。今回の最終承認により、LUMRYZは、ナルコレプシー患者向けにFDAが承認した最初で唯一の就寝時1回投与のオキシベート製剤となります。さらに、LUMRYZはFDAから希少疾病用医薬品としての独占的使用権を付与されています。

当レポートでは、世界の睡眠補助市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の睡眠補助市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 製品別
    • 睡眠障害別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • 製品別
    • 睡眠障害別
    • エンドユーザー別
    • 地域別

第5章 北米の睡眠補助市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 製品別
    • 睡眠障害別
    • シェア：国別
  • 各国の市場の評価
    • 米国の睡眠補助市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州の睡眠補助市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋の睡眠補助市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の睡眠補助市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの睡眠補助市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 輸入と輸出の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場促進要因
  • 市場の課題

第17章 市場の動向と発展

第18章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第19章 特許情勢

第20章 ケーススタディ

第21章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • BMC Medical Co., Ltd.
    • Cadwell Industries, Inc.
    • Compumedics Limited
    • Fisher & Paykel Healthcare Limited
    • Merck& Co., Inc.
    • Natus Medical Inc.
    • Koninklijke Philips N.V.
    • Pfizer Inc.
    • Sanofi S.A.
    • SleepMed Inc.

第22章 戦略的推奨

第23章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 3. Global Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 4. Global Sleep Aids Market Share (%), By Region, 2017-2031F
  • Figure 5. North America Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 6. North America Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 7. North America Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 8. North America Sleep Aids Market Share (%), By Country, 2017-2031F
  • Figure 9. United States Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. United States Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 11. United States Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 12. Canada Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 13. Canada Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 14. Canada Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 15. Mexico Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Mexico Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 17. Mexico Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 18. Europe Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Europe Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 20. Europe Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 21. Europe Sleep Aids Market Share (%), By Country, 2017-2031F
  • Figure 22. Germany Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 23. Germany Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 24. Germany Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 25. France Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 26. France Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 27. France Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 28. Italy Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Italy Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 30. Italy Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 31. United Kingdom Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. United Kingdom Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 33. United Kingdom Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 34. Russia Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Russia Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 36. Russia Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 37. Netherlands Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 38. Netherlands Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 39. Netherlands Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 40. Spain Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Spain Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 42. Spain Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 43. Turkey Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Turkey Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 45. Turkey Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 46. Poland Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Poland Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 48. Poland Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 49. South America Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. South America Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 51. South America Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 52. South America Sleep Aids Market Share (%), By Country, 2017-2031F
  • Figure 53. Brazil Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. Brazil Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 55. Brazil Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 56. Argentina Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Argentina Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 58. Argentina Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 59. Asia-Pacific Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Asia-Pacific Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 61. Asia-Pacific Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 62. Asia-Pacific Sleep Aids Market Share (%), By Country, 2017-2031F
  • Figure 63. India Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 64. India Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 65. India Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 66. China Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 67. China Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 68. China Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 69. Japan Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Japan Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 71. Japan Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 72. Australia Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 73. Australia Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 74. Australia Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 75. Vietnam Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 76. Vietnam Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 77. Vietnam Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 78. South Korea Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 79. South Korea Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 80. South Korea Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 81. Indonesia Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Indonesia Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 83. Indonesia Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 84. Philippines Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Philippines Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 86. Philippines Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 87. Middle East & Africa Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 88. Middle East & Africa Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 89. Middle East & Africa Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 90. Middle East & Africa Sleep Aids Market Share (%), By Country, 2017-2031F
  • Figure 91. Saudi Arabia Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 92. Saudi Arabia Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 93. Saudi Arabia Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 94. UAE Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. UAE Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 96. UAE Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 97. South Africa Sleep Aids Market, By Value, In USD Billion, 2017-2031F
  • Figure 98. South Africa Sleep Aids Market Share (%), By Product, 2017-2031F
  • Figure 99. South Africa Sleep Aids Market Share (%), By Sleep Disorder, 2017-2031F
  • Figure 100. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 101. By Sleep Disorder Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 102. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX12169

Global sleep aids market is projected to witness a CAGR of 6.46% during the forecast period 2024-2031, growing from USD 81.80 billion in 2023 to USD 134.97 billion in 2031. The market for sleep aids is anticipated to grow at a faster pace under the influence of rising cases of sleep disorders, increased R&D initiatives around sleep disorders, and heightened awareness about sound sleep and its health implications.

Products that help individuals sleep better and mitigate sleep disorders, including insomnia, sleep apnea, and restless leg syndrome, are referred to as sleep aids. This option includes prescription medications, over-the-counter supplements, herbal remedies, and newer technologies such as a sleep-tracking device and smart mattresses. Sleep aids have experienced a highly increasing demand in recent years, heralded by the very awareness of the increasing need for sleep as an integral part of health and wellbeing. Increased stress levels, busy lifestyles, and widespread influences of technological gadgets have also contributed to disturbances in sleep. As the ill effects of sleep deprivation on health become more and more apparent, increasingly more individuals seek natural remedies to eliminate this issue. The pandemic has further fueled these rising needs, with many people experiencing heightened anxiety levels and disturbances in their sleep. These conditions made customers seek a cure, and at the same time, increased pressure on healthcare professionals to recommend sleep aids. As more and more people come forward to discuss mental disorders, product innovation, and increased tolerance toward mental health issues, the sleep aid market continues to gain momentum, thus bringing significant interest to both consumer groups and businesses.

In May 2023, Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to improve lives, announced that the U.S. Food & Drug Administration (FDA) has granted final approval to LUMRYZ. LUMRYZ is an extended-release formulation of sodium oxybate intended to be taken once at bedtime for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. With this final approval, LUMRYZ becomes the first and only FDA-approved once-at-bedtime oxybate for people living with narcolepsy. Additionally, LUMRYZ has been granted Orphan Drug Exclusivity by the FDA.

Rising Sleep Troubles Among People to Boost Market Demand

The growing incidence of sleeping disorders is generating high demand for sleep aids all over the world. There are several reasons for this. The elderly population is more prone to sleeping problems, and the related customer base is huge. Other factors for the increase of sleep disorders including modern lifestyle are stress levels, irregular work hours, and increased time in front of screens, which have disrupted normal sleep cycles in almost all the strata of the population. Public awareness of the need for sleep for overall health leads people to seek effective solutions further and thus increases market demand. Improving technology in sleeping aids, such as wearable devices and smart beds, also upgrades the product offerings and attracts consumers. According to the data of the National Council of Aging, around 39 million adults in the United States suffer from obstructive sleep apnea (OSA) and the number goes up to 936 million adults around the world who have mild to severe OSA. Snoring is a common symptom of sleep apnea in up to 94% of patients.

Growing Focus on R&D for Sleeping Aids to Bring Market Growth

The growth in R&D for sleep aids is expected to propel the market forward. As the issues relating to sleep, such as sleep apnea and insomnia, are increasing, there is a greater demand for a better solution. R&D initiatives have also led to the manufacturing of unique products, natural supplements, and sophisticated sleep technologies, catering to the diverse needs of the consumer. Companies, as well as startup firms, invest heavily in R&D, exploring various new compounds, formulations, as well as delivery methods, that can better improve the quality of sleep without adverse effects. Such products are validated through clinical trials and scientific studies, while consumer confidence generated by those studies boosts adoption. For instance, in July 2024, Corundum Neuroscience awarded a research grant to Tel Aviv University to develop a machine learning-based method for the non-invasive detection of abnormal brain activity in deep brain regions during sleep. The project aims to identify brain activity linked to dementia using high-density EEG. The goal is to create disease-specific biomarkers for neurodegenerative conditions and improve diagnostics and treatment.

Insomnia Segment to Dominate the Market

The insomnia market segment is expected to lead the sleep aid market, as sleeping disorders are on the rise and more people become aware of their health implications. The rising insomnia rates due to stress, anxiety, and lifestyle issues keep more people searching for a healthy solution that would provide them with better quality sleep. Such chronic insomnia affects a large portion of the population, and thus the demand for specialty products, such as prescription medications, over-the-counter supplements, or natural remedies is high. The emergence of new, insomnia-specific formulations and products is also on the rise, enhancing effectiveness and consumer acceptability. Strategic product launches for insomnia treatment further increase its market share, for instance, in July 2024, Jiangsu Simcere Pharmaceutical Co., Ltd. announced that the National Medical Products Administration has accepted the new drug application for Quviviq (daridorexant hydrochloride tablets), an innovative anti-insomnia drug developed in collaboration with Idorsia of Switzerland. Quviviq is a dual orexin receptor antagonist (DORA) and represents a new generation of anti-insomnia drugs. The drug has been approved for marketing in nine countries, including the United States, the United Kingdom, Switzerland, and Canada.

North America Dominates Sleep Aids Market

North America highly dominates the market for sleep aids. Several interrelated factors have placed the region at the top. The first reason is that North America, combined with lifestyle stressors, displays one of the highest rates of sleep disorders, especially insomnia and sleep apnea. Increased screen time and fast-paced work culture have led to this rising prevalence, increasing consumer awareness and demand for effective solutions to sleep issues. Advanced healthcare infrastructure and significant investments in research and development characterize North America as well. The majors, as well as startups, always are innovation and product launch leaders as they develop new sleep aids, prescription as well as over-the-counter formulations for consumers to avail. Culturally, it is pushing further the market with health and wellness awareness that more consumers are eager to find natural and holistic remedies besides pharmaceuticals.

Future Market Scenario (2024-2031F)

Smart mattresses equipped with AI integration are poised to drive significant growth in the sleep aids market. These innovative products utilize advanced sensors to monitor sleep patterns, heart rates, and breathing, providing real-time feedback and personalized sleep recommendations. By adjusting firmness, temperature, and support based on individual needs, smart mattresses enhance overall sleep quality. Furthermore, AI-driven insights can help users understand their sleep behavior, encouraging healthier habits. As consumers increasingly seek personalized and tech-driven solutions to improve sleep, the demand for smart mattresses is expected to rise, positioning them as key players in the evolving sleep aids market. In November 2023, DeRUCCI Group launched the T11 Pro Smart Mattress, the first AIoT smart mattress, designed to enhance sleep quality through advanced technology. It features 23 AI sensors that monitor various health metrics, including body temperature and heart rate, and 18 support airbags that adjust to users' movements. The mattress utilizes a patented algorithm for real-time adjustments tailored to individual sleeping positions, improving spinal health by over 40%. It connects with IoT devices for a fully integrated smart bedroom experience and offers features like snoring intervention and personalized sleep reports.

Key Players Landscape and Outlook

The sleep aid market features a dynamic landscape dominated by key players across pharmaceuticals, supplements, and technology sectors. Prominent pharmaceutical companies, such as Pfizer and Merck, offer prescription medications like Zolpidem and Eszopiclone, focusing on effectiveness and safety to address chronic insomnia. Over-the-counter brands like Unisom and Tylenol cater to consumers seeking immediate relief with accessible solutions. Recent activities in the sleep aids market include regulatory approvals and joint ventures for market expansion.

In March 2024, Vanda Pharmaceuticals Inc. announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ (tasimelteon) in the treatment of insomnia characterized by difficulties with sleep initiation.

In October 2023, Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan. The joint venture, called Shionogi-Apnimed Sleep Science, LLC, will initially focus on accelerating the discovery, preclinical, and clinical development of novel pharmacologic solutions designed to address the complex pathology of OSA.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Sleep Aids Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Mattresses and Pillows
      • 4.2.1.2. Sleep Laboratory Services
      • 4.2.1.3. Medication
      • 4.2.1.4. Others
    • 4.2.2. By Sleep Disorder
      • 4.2.2.1. Insomnia
      • 4.2.2.2. Sleep Apnea
      • 4.2.2.3. Restless Legs Syndrome
      • 4.2.2.4. Narcolepsy
      • 4.2.2.5. Sleepwalking
      • 4.2.2.6. Other Sleep Disorders
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia-Pacific
      • 4.2.3.4. South America
      • 4.2.3.5. Middle East and Africa
    • 4.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Product
    • 4.3.2. By Sleep Disorder
    • 4.3.3. By End-user
    • 4.3.4. By Region

5. North America Sleep Aids Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Mattresses and Pillows
      • 5.2.1.2. Sleep Laboratory Services
      • 5.2.1.3. Medication
      • 5.2.1.4. Others
    • 5.2.2. By Sleep Disorder
      • 5.2.2.1. Insomnia
      • 5.2.2.2. Sleep Apnea
      • 5.2.2.3. Restless Legs Syndrome
      • 5.2.2.4. Narcolepsy
      • 5.2.2.5. Sleepwalking
      • 5.2.2.6. Other Sleep Disorders
    • 5.2.3. By Country Share
      • 5.2.3.1. United States
      • 5.2.3.2. Canada
      • 5.2.3.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Sleep Aids Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Product
          • 5.3.1.2.1.1. Mattresses and Pillows
          • 5.3.1.2.1.2. Sleep Laboratory Services
          • 5.3.1.2.1.3. Medication
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Sleep Disorder
          • 5.3.1.2.2.1. Insomnia
          • 5.3.1.2.2.2. Sleep Apnea
          • 5.3.1.2.2.3. Restless Legs Syndrome
          • 5.3.1.2.2.4. Narcolepsy
          • 5.3.1.2.2.5. Sleepwalking
          • 5.3.1.2.2.6. Other Sleep Disorders
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Sleep Aids Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Sleep Aids Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Sleep Aids Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Sleep Aids Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. BMC Medical Co., Ltd.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Cadwell Industries, Inc.
    • 21.3.3. Compumedics Limited
    • 21.3.4. Fisher & Paykel Healthcare Limited
    • 21.3.5. Merck& Co., Inc.
    • 21.3.6. Natus Medical Inc.
    • 21.3.7. Koninklijke Philips N.V.
    • 21.3.8. Pfizer Inc.
    • 21.3.9. Sanofi S.A.
    • 21.3.10. SleepMed Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer